Guillermo Izquierdo
A5112746430- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Systemic Sclerosis and Related Diseases
- Acute Lymphoblastic Leukemia research
- Sphingolipid Metabolism and Signaling
- Immunotherapy and Immune Responses
- Viral Infections and Immunology Research
- T-cell and B-cell Immunology
- Cytokine Signaling Pathways and Interactions
- Health Systems, Economic Evaluations, Quality of Life
- Vascular Malformations Diagnosis and Treatment
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Reproductive System and Pregnancy
- Olfactory and Sensory Function Studies
- Monoclonal and Polyclonal Antibodies Research
- Mycobacterium research and diagnosis
- RNA regulation and disease
- Chronic Lymphocytic Leukemia Research
- Long-Term Effects of COVID-19
- Intracranial Aneurysms: Treatment and Complications
- SARS-CoV-2 and COVID-19 Research
Hospital Universitario Virgen Macarena
2016-2025
Universidad de Sevilla
2009-2025
Secretaría de Educación del Distrito Capital
2024
Hospitales Nisa
2019-2023
The University of Melbourne
2014-2023
Griffith University
2023
Barwon Health
2023
The University of Queensland
2023
QIMR Berghofer Medical Research Institute
2023
University of Tasmania
2023
Fingolimod (FTY720), a sphingosine-1-phosphate–receptor modulator that prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement on imaging in phase 2 study involving patients with multiple sclerosis.
<h3>Importance</h3> Within 2 decades of onset, 80% untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase irreversible disability accrual termed secondary progressive MS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied never using validated definition. <h3>Objective</h3> To determine the use, type of, timing DMTs risk MS diagnosed <h3>Design, Setting, Participants</h3> Cohort study prospective data from...
A number of studies have been conducted with the onset secondary progressive multiple sclerosis as an inclusion criterion or outcome interest. However, a standardized objective definition has lacking. The aim this work was to evaluate accuracy and feasibility for sclerosis, enable comparability future research studies. Using MSBase, large, prospectively acquired, global cohort study, we analysed 576 data-derived definitions first compared these consensus opinion three neurologists. All were...
A female/male (F/M) ratio increase over time in multiple sclerosis (MS) patients was demonstrated many countries around the world. So far, a direct comparison of sex time-trends among MS populations from different geographical areas not carried out.In this paper we assessed and compared trends, 60-year span, belonging to latitudinal areas.Data cohort 15,996 (F = 11,290; M 4,706) definite with birth years ranging 1930 1989 were extracted international MSBase registry New Zealand database....
Prevention of irreversible disability is currently the most important goal disease modifying therapy for multiple sclerosis. The outcomes used in clinical trials rely on progression Expanded Disability Status Scale score confirmed over 3 or 6 months. However, sensitivity and stability this metric has not been extensively evaluated. Using global MSBase cohort study, we evaluated 48 criteria progression, testing three definitions baseline disability, two magnitude, long-term irreversibility...
To identify predictors of 10-year Expanded Disability Status Scale (EDSS) change after treatment initiation in patients with relapse-onset multiple sclerosis.Using data obtained from MSBase, we defined baseline as the date first injectable therapy initiation. Patients need only have remained on for 1 day and were monitored any approved disease-modifying therapy, or no thereafter. Median EDSS score changes over a period determined. Predictors then assessed using median quantile regression...
Multiple sclerosis (MS) is a chronic relapsing disease of the central nervous system (CNS) in which immune processes are believed to play major role. To date, there no reliable method by characterize and their changes associated with different forms MS progression. We performed antigen microarray analysis patterns antibody reactivity serum against panel CNS protein lipid autoantigens heat shock proteins. Informatic consisted training set that was validated on blinded test set. The results...
Observational cohort studies are a powerful tool to assess the long-term outcome in chronic diseases. This study design has been utilized local and regional multiple sclerosis (MS) yielded invaluable epidemiological information. The World Wide Web now provides an excellent opportunity for international, collaborative of MS outcomes. A web platform--MSBase--has designed collect prospective data on patients with MS. It is purely observational, enabling participating neurologists contribute...
Background: Several studies have shown that pregnancy reduces multiple sclerosis (MS) relapses, which increase in the early postpartum period. Postpartum relapse risk has been predicted by pre-pregnancy disease activity some studies. Objective: To re-examine effect of on relapses using large international MSBase Registry, examining predictors relapse. Methods: An observational case–control study was performed including pregnancies post-MS onset. Annualised rate (ARR) and median Expanded...
The aim of this work was to evaluate sex differences in the incidence multiple sclerosis relapses; assess relationship between and primary progressive disease course; compare effects age duration on relapse incidence. Annualized rates were calculated using MSBase registry. Patients with incomplete data or <1 year follow-up excluded. only included ratio analysis. Relapse incidences over 40 years 70 compared females males Andersen-Gill Tweedie models. Female-to-male ratios stratified by annual...
Objective In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians often switch therapy to either natalizumab fingolimod. However, no studies have directly compared the outcomes of switching these agents. Methods Using MSBase, a large international, observational, prospectively acquired cohort study, we identified relapsing–remitting experiencing relapses disability progression within 6 months immediately preceding...
Background Multiple Sclerosis is more common in women than men and females have relapses men. In a large international cohort we evaluated the effect of gender on disability accumulation disease progression to determine if male MS patients worse clinical outcome females. Methods Using MSBase Registry, data from 15,826 25 countries was analysed. Changes severity (EDSS) were compared between sexes using repeated measures analysis generalised linear mixed models. Kaplan-Meier used test for sex...
To evaluate immune responses in fingolimod-treated patients with multiple sclerosis (MS) against influenza vaccine (to test for anticipated novel antigens seronegative patients) and recall (tetanus toxoid [TT] booster dose) antigens.This was a blinded, randomized, multicenter, placebo-controlled study. Patients aged 18 to 55 years relapsing MS were randomized (2:1) fingolimod 0.5 mg or placebo 12 weeks. At week 6, received seasonal (containing of California, Perth, Brisbane virus strains) TT...
<h3>Background:</h3> <i>IRF5</i> is a transcription factor involved both in the type I interferon and toll-like receptor signalling pathways. Previously, has been found to be associated with systemic lupus erythematosus, rheumatoid arthritis inflammatory bowel diseases. Here we investigated whether polymorphisms gene would yet another disease features of autoimmunity, multiple sclerosis (MS). <h3>Methods:</h3> We genotyped nine single nucleotide one insertion-deletion polymorphism collection...
The human leukocyte antigen (HLA) DRB1*1501 has been consistently associated with multiple sclerosis (MS) in nearly all populations tested. This points to a specific presentation as the pathogenic mechanism though this does not fully explain disease association. identification of expression quantitative trait loci (eQTL) for genes HLA locus poses question role gene MS susceptibility. We analyzed eQTLs region respect MS-associated HLA-variants obtained from genome-wide association studies...
<h3>Objective:</h3> To determine early risk of relapse after switch from natalizumab to fingolimod; compare the experience that in patients switching interferon-β/glatiramer acetate (IFN-β/GA) and those previously treatment naive; predictors time first on fingolimod. <h3>Methods:</h3> Data were obtained MSBase Registry. Relapse rates (RRs) for each patient group compared using adjusted negative binomial regression. Survival analyses coupled with Cox regression used model <h3>Results:</h3> A...
Currently available treatments for secondary progressive multiple sclerosis(SPMS) have limited efficacy and/or safety concerns. Adipose-mesenchymal derived stem cells(AdMSCs) represent a promising option and can be readily obtained using minimally invasive procedures.In this triple-blind, placebo-controlled study, cell samples were from consenting patients by lipectomy subsequently expanded. Patients randomized to single infusion of placebo, low-dose(1x106cells/kg) or...
To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes first line MS at these using propensity scoring to adjust for baseline imbalance characteristics.Treatment discontinuations were evaluated all patients within the MSBase who commenced SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical 1220 treated with either dosage (22 µg or 44 µg) as their modifying agent, matched on...
Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response varies greatly among patients. Comprehensive predictive models individual are lacking. Our aims were: (i) to develop algorithms using demographic, clinical and paraclinical predictors patients with (ii) evaluate accuracy, internal external validity these algorithms. This study evaluated 27 seven disease-modifying therapies MSBase, a large global cohort study....